Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hodgkin Disease 20Lymphoma 6Urinary Bladder Neoplasms 3Urothelial Carcinoma of the Bladder 1Rhabdoid Tumor 1Renal Pelvis and Ureter Urothelial Carcinoma 1Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Lymphoma, Large-Cell, Anaplastic 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Choroid Plexus Neoplasms 1Childhood Solid Tumor 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Astrocytoma 1

Interventions

Specimen Handling 2Biopsy 2pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1enfortumab vedotin 1durvalumab 1Vinblastine 1Platinum 1Nephroureterectomy 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Pelvis and Ureter Urothelial Carcinoma × Vinblastine × 1 year × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡